Advertisement

Cancer and Metastasis Reviews

, Volume 29, Issue 2, pp 285–293 | Cite as

Hypoxia, inflammation, and the tumor microenvironment in metastatic disease

  • Elizabeth C. Finger
  • Amato J. GiacciaEmail author
Article

Abstract

Metastasis, the leading cause of cancer deaths, is an intricate process involving many important tumor and stromal proteins that have yet to be fully defined. This review discusses critical components necessary for the metastatic cascade, including hypoxia, inflammation, and the tumor microenvironment. More specifically, this review focuses on tumor cell and stroma interactions, which allow cell detachment from a primary tumor, intravasation to the blood stream, and extravasation at a distant site where cells can seed and tumor metastases can form. Central players involved in this process and discussed in this review include integrins, matrix metalloproteinases, and soluble growth factors/matrix proteins, including the connective tissue growth factor and lysyl oxidase.

Keywords

Connective tissue growth factor Lysyl oxidase Metastasis Hypoxia 

Notes

Acknowledgments

Due to the broad scope of this review, we apologize to anyone we failed to cite. This work was supported by the National Institutes of Health (RO1 CA-116685, PO1 CA-67166, and T32 CA121940 to E.C.F and to A.J.G.).

References

  1. 1.
    Jemal, A., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4), 225–249.CrossRefGoogle Scholar
  2. 2.
    Krug, E. L., Mjaatvedt, C. H., & Markwald, R. R. (1987). Extracellular matrix from embryonic myocardium elicits an early morphogenetic event in cardiac endothelial differentiation. Developmental Biology, 120(2), 348–355.PubMedCrossRefGoogle Scholar
  3. 3.
    Hay, E. D. (1995). An overview of epithelio-mesenchymal transformation. Acta Anatomica (Basel), 154(1), 8–20.CrossRefGoogle Scholar
  4. 4.
    Tarin, D., Thompson, E. W., & Newgreen, D. F. (2005). The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Research, 65(14), 5996–6000. discussion 6000-1.PubMedCrossRefGoogle Scholar
  5. 5.
    Birchmeier, W., & Behrens, J. (1994). Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochimica et Biophysica Acta, 1198(1), 11–26.PubMedGoogle Scholar
  6. 6.
    Hotz, B., et al. (2007). Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clinical Cancer Research, 13(16), 4769–4776.PubMedCrossRefGoogle Scholar
  7. 7.
    Gravdal, K., et al. (2007). A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research, 13(23), 7003–7011.PubMedCrossRefGoogle Scholar
  8. 8.
    Margulis, A., et al. (2005). E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs. Cancer Research, 65(5), 1783–1791.PubMedCrossRefGoogle Scholar
  9. 9.
    Yilmaz, M., & Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews, 28(1–2), 15–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Haraguchi, M., et al. (2008). Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins. Journal of Biological Chemistry, 283(35), 23514–23523.PubMedCrossRefGoogle Scholar
  11. 11.
    Gordon, K. J., et al. (2008). Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis, 29(2), 252–262.PubMedCrossRefGoogle Scholar
  12. 12.
    Ozdamar, B., et al. (2005). Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science, 307(5715), 1603–1609.PubMedCrossRefGoogle Scholar
  13. 13.
    Dumont, N., Bakin, A. V., & Arteaga, C. L. (2003). Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. Journal of Biological Chemistry, 278(5), 3275–3285.PubMedCrossRefGoogle Scholar
  14. 14.
    Kalluri, R. (2003). Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews Cancer, 3(6), 422–433.PubMedCrossRefGoogle Scholar
  15. 15.
    Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332–337.PubMedCrossRefGoogle Scholar
  16. 16.
    Desgrosellier, J. S., & Cheresh, D. A. (2010). Integrins in cancer: Biological implications and therapeutic opportunities. Nataure Reviews Cancer, 10(1), 9–22.CrossRefGoogle Scholar
  17. 17.
    Takayama, S., et al. (2005). The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Research, 25(1A), 79–83.PubMedGoogle Scholar
  18. 18.
    Liapis, H., Flath, A., & Kitazawa, S. (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagnostic Molecular Pathology, 5(2), 127–135.PubMedCrossRefGoogle Scholar
  19. 19.
    McCabe, N. P., et al. (2007). Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene, 26(42), 6238–6243.PubMedCrossRefGoogle Scholar
  20. 20.
    Hosotani, R., et al. (2002). Expression of integrin alphaVbeta3 in pancreatic carcinoma: Relation to MMP-2 activation and lymph node metastasis. Pancreas, 25(2), e30–e35.PubMedCrossRefGoogle Scholar
  21. 21.
    Gruber, G., et al. (2005). Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. British Journal of Cancer, 92(1), 41–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Landen, C. N., et al. (2008). Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia, 10(11), 1259–1267.PubMedGoogle Scholar
  23. 23.
    Bello, L., et al. (2001). Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery, 49(2), 380–9. discussion 390.PubMedCrossRefGoogle Scholar
  24. 24.
    Mullamitha, S. A., et al. (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clinincal Cancer Reseach, 13(7), 2128–2135.CrossRefGoogle Scholar
  25. 25.
    Ricart, A. D., et al. (2008). Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study. Clinical Cancer Research, 14(23), 7924–7929.PubMedCrossRefGoogle Scholar
  26. 26.
    Gross, J., & Lapiere, C. M. (1962). Collagenolytic activity in amphibian tissues: A tissue culture assay. Proceedings of the National Academy of Science of the United States America, 48, 1014–1022.CrossRefGoogle Scholar
  27. 27.
    Brinckerhoff, C. E., & Matrisian, L. M. (2002). Matrix metalloproteinases: A tail of a frog that became a prince. Nature Reviews Molecular Cell Biology, 3(3), 207–214.PubMedCrossRefGoogle Scholar
  28. 28.
    Burrage, P., et al. (2006). Matrix metalloproteinases: Role in arthritis. Frontiers in Bioscience, 11, 529–543.Google Scholar
  29. 29.
    Zucker, S., et al. (1999). Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Annals of the New York Academy of Sciences, 878, 212–227.PubMedCrossRefGoogle Scholar
  30. 30.
    Koc, M., et al. (2006). Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori, 92(2), 149–154.PubMedGoogle Scholar
  31. 31.
    Hilska, M., et al. (2007). Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. International Journal of Cancer, 121(4), 714–723.CrossRefGoogle Scholar
  32. 32.
    Lengyel, E., et al. (2001). Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecologic Oncology, 82(2), 291–298.PubMedCrossRefGoogle Scholar
  33. 33.
    Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287–5297.PubMedCrossRefGoogle Scholar
  34. 34.
    Dublanchet, A. C., et al. (2005). Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorganic & Medicinal Chemistry Letters, 15(16), 3787–3790.CrossRefGoogle Scholar
  35. 35.
    Chan, D. A., & Giaccia, A. J. (2007). Hypoxia, gene expression, and metastasis. Cancer and Metastasis Reviews, 26(2), 333–339.PubMedCrossRefGoogle Scholar
  36. 36.
    Masson, N., et al. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO Journal, 20(18), 5197–5206.PubMedCrossRefGoogle Scholar
  37. 37.
    Chan, D. A., et al. (2002). Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. Journal Biological Chemistry, 277(42), 40112–40117.CrossRefGoogle Scholar
  38. 38.
    Bedogni, B., & Powell, M. B. (2009). Hypoxia, melanocytes and melanoma—Survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Research, 22(2), 166–174.PubMedCrossRefGoogle Scholar
  39. 39.
    Epstein, A. C., et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107(1), 43–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Jaakkola, P., et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292(5516), 468–472.PubMedCrossRefGoogle Scholar
  41. 41.
    Mole, D. R., et al. (2009). Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. Journal of Biological Chemistry, 284(25), 16767–16775.PubMedCrossRefGoogle Scholar
  42. 42.
    Michieli, P. (2009). Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe? Cell Cycle, 8(20), 3291–3296.PubMedGoogle Scholar
  43. 43.
    Kim, J. W., et al. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3(3), 177–185.PubMedCrossRefGoogle Scholar
  44. 44.
    Bindra, R. S., et al. (2005). Alterations in DNA repair gene expression under hypoxia: Elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences, 1059, 184–195.PubMedCrossRefGoogle Scholar
  45. 45.
    Tang, N., et al. (2004). Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell, 6(5), 485–495.PubMedCrossRefGoogle Scholar
  46. 46.
    Pennacchietti, S., et al. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3(4), 347–361.PubMedCrossRefGoogle Scholar
  47. 47.
    Canning, M. T., et al. (2001). Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Experimental Cell Research, 267(1), 88–94.PubMedCrossRefGoogle Scholar
  48. 48.
    Esteban, M. A., et al. (2006). Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Research, 66(7), 3567–3575.PubMedCrossRefGoogle Scholar
  49. 49.
    Imai, T., et al. (2003). Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. American Journal of Pathology, 163(4), 1437–1447.PubMedGoogle Scholar
  50. 50.
    Jiang, Y. G., et al. (2007). Role of Wnt/beta-catenin signaling pathway in epithelial–mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. International Journal of Urology, 14(11), 1034–1039.PubMedCrossRefGoogle Scholar
  51. 51.
    Erler, J. T., et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440(7088), 1222–1226.PubMedCrossRefGoogle Scholar
  52. 52.
    Dewhirst, M. W., et al. (1989). Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. International Journal of Radiation Oncology, Biology, Physics, 17(1), 91–99.PubMedGoogle Scholar
  53. 53.
    Jain, R. K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307(5706), 58–62.PubMedCrossRefGoogle Scholar
  54. 54.
    Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86(3), 353–364.PubMedCrossRefGoogle Scholar
  55. 55.
    Shweiki, D., et al. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359(6398), 843–845.PubMedCrossRefGoogle Scholar
  56. 56.
    Holash, J., et al. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 284(5422), 1994–1998.PubMedCrossRefGoogle Scholar
  57. 57.
    Ruan, K., Song, G., & Ouyang, G. (2009). Role of hypoxia in the hallmarks of human cancer. Journal Cell Biochemistry, 107(6), 1053–1062.CrossRefGoogle Scholar
  58. 58.
    Laderoute, K. R., et al. (2000). Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clinincal Cancer Research, 6(7), 2941–2950.Google Scholar
  59. 59.
    Talks, K. L., et al. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. American Journal of Pathology, 157(2), 411–421.PubMedGoogle Scholar
  60. 60.
    Kallman, R. F., & Dorie, M. J. (1986). Tumor oxygenation and reoxygenation during radiation therapy: Their importance in predicting tumor response. International Journal of Radiation Oncology, Biology, Physics, 12(4), 681–685.PubMedGoogle Scholar
  61. 61.
    Daruwalla, J., & Christophi, C. (2006). Hyperbaric oxygen therapy for malignancy: A review. World Journal of Surgery, 30(12), 2112–2131.PubMedCrossRefGoogle Scholar
  62. 62.
    Engert, A. (2005). Recombinant human erythropoietin in oncology: Current status and further developments. Annals of Oncology, 16(10), 1584–1595.PubMedCrossRefGoogle Scholar
  63. 63.
    Galluzzo, M., et al. (2009). Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. Journal of Clinical Investigative, 119(4), 865–875.CrossRefGoogle Scholar
  64. 64.
    Csiszar, K. (2001). Lysyl oxidases: A novel multifunctional amine oxidase family. Progress in Nucleic Acid Research and Molecular Biology, 70, 1–32.PubMedCrossRefGoogle Scholar
  65. 65.
    Pinnell, S. R., & Martin, G. R. (1968). The cross-linking of collagen and elastin: Enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proceedings of the National Academy of Science of the United States of America, 61(2), 708–716.CrossRefGoogle Scholar
  66. 66.
    Trackman, P. C., et al. (1992). Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. Journal of Biological Chemistry, 267(12), 8666–8671.PubMedGoogle Scholar
  67. 67.
    Cronshaw, A. D., Fothergill-Gilmore, L. A., & Hulmes, D. J. (1995). The proteolytic processing site of the precursor of lysyl oxidase. Biochemical Journal, 306(Pt 1), 279–284.PubMedGoogle Scholar
  68. 68.
    Panchenko, M. V., et al. (1996). Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase. Journal of Biological Chemistry, 271(12), 7113–7119.PubMedCrossRefGoogle Scholar
  69. 69.
    Nellaiappan, K., et al. (2000). Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth-muscle cells. Journal of Cell Biochemistry, 79(4), 576–582.CrossRefGoogle Scholar
  70. 70.
    Kagan, H. M., & Li, W. (2003). Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. Journal of Cell Biochemistry, 88(4), 660–672.CrossRefGoogle Scholar
  71. 71.
    Kagan, H. M., et al. (1983). Histone H1 is a substrate for lysyl oxidase and contains endogenous sodium borotritide-reducible residues. Biochemical and Biophysical Research Communications, 115(1), 186–192.PubMedCrossRefGoogle Scholar
  72. 72.
    Giampuzzi, M., Oleggini, R., & Di Donato, A. (2003). Demonstration of in vitro interaction between tumor suppressor lysyl oxidase and histones H1 and H2: Definition of the regions involved. Biochimica et Biophysica Acta, 1647(1–2), 245–251.PubMedGoogle Scholar
  73. 73.
    Warburton, D., & Shi, W. (2005). Lo, and the niche is knit: Lysyl oxidase activity and maintenance of lung, aorta, and skin integrity. American Journal of Pathology, 167(4), 921–922.PubMedGoogle Scholar
  74. 74.
    Maki, J. M., et al. (2005). Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues. American Journal of Pathology, 167(4), 927–936.PubMedGoogle Scholar
  75. 75.
    Maki, J. M., et al. (2002). Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation, 106(19), 2503–2509.PubMedCrossRefGoogle Scholar
  76. 76.
    Hornstra, I. K., et al. (2003). Lysyl oxidase is required for vascular and diaphragmatic development in mice. Journal of Biology Chemistry, 278(16), 14387–14393.CrossRefGoogle Scholar
  77. 77.
    Hayashi, K., et al. (2004). Comparative immunocytochemical localization of lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL) proteins: Changes in the expression of LOXL during development and growth of mouse tissues. Journal of Molecular Histology, 35(8–9), 845–855.PubMedCrossRefGoogle Scholar
  78. 78.
    Kagan, H. M., et al. (1986). Ultrastructural immunolocalization of lysyl oxidase in vascular connective tissue. Journal of Cell Biology, 103(3), 1121–1128.PubMedCrossRefGoogle Scholar
  79. 79.
    Sakai, M., et al. (2009). Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Annals of Surgical Oncology, 16(9), 2494–2501.PubMedCrossRefGoogle Scholar
  80. 80.
    Albinger-Hegyi, A., et al. (2009). Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). International Journal of Cancer, 126(11), 2653–2662.Google Scholar
  81. 81.
    Le, Q. T., et al. (2009). Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. Journal of Clinical Oncology, 27(26), 4281–4286.PubMedCrossRefGoogle Scholar
  82. 82.
    Erler, J. T., & Giaccia, A. J. (2006). Lysyl oxidase mediates hypoxic control of metastasis. Cancer Research, 66(21), 10238–10241.PubMedCrossRefGoogle Scholar
  83. 83.
    Kirschmann, D. A., et al. (2002). A molecular role for lysyl oxidase in breast cancer invasion. Cancer Research, 62(15), 4478–4483.PubMedGoogle Scholar
  84. 84.
    Giampuzzi, M., et al. (2005). Beta-catenin signaling and regulation of cyclin D1 promoter in NRK-49F cells transformed by down-regulation of the tumor suppressor lysyl oxidase. Biochimica et Biophysica Acta, 1745(3), 370–381.PubMedGoogle Scholar
  85. 85.
    Peinado, H., et al. (2005). A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO Journal, 24(19), 3446–3458.PubMedCrossRefGoogle Scholar
  86. 86.
    Higgins, D. F., et al. (2004). Hypoxic induction of Ctgf is directly mediated by Hif-1. American Journal of Physiology. Renal Physiology, 287(6), F1223–F1232.PubMedCrossRefGoogle Scholar
  87. 87.
    Bork, P. (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Letters, 327(2), 125–130.PubMedCrossRefGoogle Scholar
  88. 88.
    Wenger, C., et al. (1999). Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene, 18(4), 1073–1080.PubMedCrossRefGoogle Scholar
  89. 89.
    Xie, D., et al. (2004). Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clinical Cancer Research, 10(6), 2072–2081.PubMedCrossRefGoogle Scholar
  90. 90.
    Kubo, M., et al. (1998). Expression of fibrogenic cytokines in desmoplastic malignant melanoma. British Journal of Dermatology, 139(2), 192–197.PubMedCrossRefGoogle Scholar
  91. 91.
    Shimo, T., et al. (2001). Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Letters, 174(1), 57–64.PubMedCrossRefGoogle Scholar
  92. 92.
    Hartel, M., et al. (2004). Desmoplastic reaction influences pancreatic cancer growth behavior. World Journal of Surgery, 28(8), 818–825.PubMedCrossRefGoogle Scholar
  93. 93.
    Bennewith, K. L., et al. (2009). The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Research, 69(3), 775–784.PubMedCrossRefGoogle Scholar
  94. 94.
    Dornhofer, N., et al. (2006). Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Research, 66(11), 5816–5827.PubMedCrossRefGoogle Scholar
  95. 95.
    Dammeier, J., et al. (1998). Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? International Journal of Biochemistry and Cell Biology, 30(8), 909–922.PubMedCrossRefGoogle Scholar
  96. 96.
    Igarashi, A., et al. (1996). Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. Journal of Investigative Dermatology, 106(4), 729–733.PubMedCrossRefGoogle Scholar
  97. 97.
    Ito, Y., et al. (1998). Expression of connective tissue growth factor in human renal fibrosis. Kidney International, 53(4), 853–861.PubMedCrossRefGoogle Scholar
  98. 98.
    Kondo, S., et al. (2002). Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis, 23(5), 769–776.PubMedCrossRefGoogle Scholar
  99. 99.
    Koliopanos, A., et al. (2002). Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World Journal of Surgery, 26(4), 420–427.PubMedCrossRefGoogle Scholar
  100. 100.
    Shakunaga, T., et al. (2000). Expression of connective tissue growth factor in cartilaginous tumors. Cancer, 89(7), 1466–1473.PubMedCrossRefGoogle Scholar
  101. 101.
    Kuper, H., Adami, H. O., & Trichopoulos, D. (2000). Infections as a major preventable cause of human cancer. Journal of Internal Medicine, 248(3), 171–183.PubMedCrossRefGoogle Scholar
  102. 102.
    Pisani, P., et al. (1997). Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiology, Biomarkers and Prevention, 6(6), 387–400.PubMedGoogle Scholar
  103. 103.
    Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867.PubMedCrossRefGoogle Scholar
  104. 104.
    Wu, Y., & Zhou, B. P. (2010). TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer, 102(4), 639–644.PubMedCrossRefGoogle Scholar
  105. 105.
    Schoppmann, S. F., et al. (2002). Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. American Journal of Pathology, 161(3), 947–956.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Radiation and Cancer Biology, Department of Radiation OncologyStanford UniversityStanfordUSA

Personalised recommendations